Drug intelligence / Profile preview

Aleomig

Development stage: Unknown
Lead developer: Aleonat
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Aleomig is an over-the-counter herbal dietary supplement developed by the Tunisian phytotherapy company Aleonat. Formulated as oral capsules, it is designed to prevent and relieve migraines and headaches. The product contains a blend of natural botanical extracts, including feverfew (*Tanacetum parthenium*), ginger (*Zingiber officinale*), guarana, white willow (*Salix alba*), fumitory, hawthorn, lavender, and lemon balm. These ingredients work synergistically to provide analgesic, anti-inflammatory, and sedative effects, helping to reduce the frequency and intensity of migraine attacks.

Brand names: Aleomig
Other names: Aleonat Aleomig

Beyond the preview

Go deeper on Aleomig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aleomig.

Explore the full profile